You notice it first at the temples, or maybe the crown — the hair is still there, but it’s finer, shorter, slower to grow back. This isn’t random. There’s a specific biological mechanism behind it, and understanding how it works is the difference between picking a treatment that targets the actual cause and spending money on products that don’t stand a chance of working.
Here’s what tends to happen instead. You spend months — sometimes years — adjusting your haircut, changing your parting, buying volumising shampoos that promise the world and deliver very little. The emotional energy that goes into managing how it looks, rather than understanding why it’s happening, is enormous. And by the time most men start asking real questions about the biology, they’ve already lost ground they didn’t have to lose. Understanding the mechanism isn’t a detour. It’s the starting point.
What is actually happening inside the follicle when hair starts thinning
The DHT molecule — what it is, where it comes from, and why your follicles react to it
The central character in male pattern hair loss is a molecule called dihydrotestosterone, or DHT. It’s produced when an enzyme called 5-alpha reductase converts testosterone — yes, the same testosterone responsible for muscle development and other male characteristics — into this more potent derivative. DHT itself isn’t harmful in most of the body. The problem is specific to certain hair follicles on your scalp, which carry a genetic sensitivity to it.
When DHT binds to receptors in these sensitive follicles, it triggers a process that gradually disrupts normal cell activity. The follicle doesn’t die immediately. It shrinks. Each hair growth cycle, the follicle produces a slightly thinner, shorter strand than before. That’s the mechanism. It’s gradual, it’s cumulative, and for most men it’s silently underway long before they consciously notice anything in the mirror.
Follicle miniaturisation explained: why hairs get finer before they disappear
Think of each hair follicle as a plant pot that gets progressively smaller every growing season. DHT doesn’t kill the root immediately — it just makes the pot a little smaller each cycle, so the plant that grows is thinner, shorter, and weaker than before. Eventually the pot is so small nothing meaningful can grow in it. This process is called follicle miniaturisation, and it’s the defining feature of androgenetic alopecia — the clinical term for male pattern hair loss.
The reason this matters practically is that miniaturised follicles that are still producing hair — even weak, fine, barely-there strands — are still alive. They can still respond to treatment. A follicle that has fully miniaturised and gone completely dormant is a much harder problem. The goal of treatment is either to stop the pot from shrinking further, or to encourage what’s left in the pot to grow as vigorously as possible. And the earlier you act, the more pot you have left to work with.
The hair growth cycle, and how DHT disrupts it
Anagen (active growth), telogen (shedding), and what DHT does to the timeline
Hair doesn’t grow continuously. It moves through distinct phases. The active growth phase — called anagen — is when the follicle is producing a hair strand. This phase typically lasts two to six years in a healthy follicle. After that, the hair transitions into a brief intermediate stage before entering telogen, the resting phase, which ends with the hair shedding and the cycle starting again.
DHT works by shortening the anagen phase in genetically sensitive follicles. Instead of spending years actively growing, affected follicles spend progressively less time growing and more time in the resting and shedding phase. The hairs produced are shorter because they simply don’t have enough growth time to reach full length. Over successive cycles, this pattern compounds — shorter anagen, finer strand, smaller follicle — until growth becomes barely detectable.
Why some follicles are affected and others are not — the role of genetic sensitivity
If you’ve ever wondered why the hair at the back and sides of your head often survives while the top thins, the answer is follicle sensitivity. The follicles at your temples and crown are genetically programmed to carry more DHT receptors than those at the sides and back. This isn’t universal — the pattern varies — but it explains the characteristic shape of male pattern hair loss that dermatologists classify using what’s known as the Norwood scale.
The categorisation of these patterns has become precise enough that researchers are now applying deep learning techniques to classify hair loss stages from photographs, with the first published work in this area completed in 2019. The point is not that AI is going to solve your hair loss — it’s that standardised staging matters clinically, because the stage you’re at determines which interventions are still likely to help. A stage II is a very different conversation from a stage VI.
It is not just genetics — the other factors that accelerate hair loss
Age, stress, and underlying health conditions as contributing triggers
Genetics determines your follicles’ sensitivity to DHT. But genetics alone doesn’t set the pace. Several other factors influence how quickly miniaturisation progresses. Chronic stress — specifically the sustained elevation of cortisol — is clinically recognised as a contributor. Cortisol can push hair follicles prematurely into the telogen (shedding) phase, a condition known as telogen effluvium. This doesn’t cause androgenetic alopecia on its own, but in someone who already has DHT sensitivity, it accelerates the visible timeline considerably.
Thyroid dysfunction, iron deficiency anaemia, and significant nutritional gaps can all compromise the hair growth cycle in ways that layer on top of DHT-driven miniaturisation. If your hair loss feels like it accelerated suddenly — after a period of intense work stress, illness, or major life change — that context is worth raising with a doctor. Male pattern hair loss is multi-factorial, and treating only the DHT component while ignoring contributing health factors is an incomplete approach.
Why hair loss can begin in your early twenties, not your forties
There’s a persistent assumption that hair loss is a middle-age problem. It isn’t. Clinically, male pattern hair loss can begin as early as the late teens or early twenties — some evidence suggests it can start around 18 in men with strong genetic predisposition. By the time you’re in your late twenties and noticing it, the process may have been quietly underway for several years. This matters because the follicle miniaturisation that occurred in those earlier years has already happened — you can’t reverse it, you can only slow what’s still in progress.
The reason this isn’t better known is partly social. Men in their twenties don’t expect to be addressing hair loss. The cultural script says this is for your father’s generation. That script is wrong, and accepting it costs real intervention time.
Why this mechanism matters when choosing a treatment
DHT-blocking approaches (finasteride) vs. follicle-stimulating approaches (minoxidil) — what each one targets
Finasteride works upstream. It inhibits the 5-alpha reductase enzyme that converts testosterone into DHT, thereby reducing the amount of DHT available to bind to follicle receptors. Less DHT, slower miniaturisation. It doesn’t regrow hair that’s already gone — it slows, and in some cases stops, the progression. This is a systemic medication, meaning it works throughout your body, not just on your scalp.
Minoxidil works differently. It’s a vasodilator — it widens the blood vessels near the follicle, improving blood flow and nutrient delivery. Minoxidil is an established topical intervention for men’s hair loss, though it doesn’t address DHT at all. It can help push miniaturised follicles back into an active growth phase, which is why it’s used alongside finasteride in many clinical protocols rather than instead of it. They target different parts of the problem. Neither is a cure.
Why a shampoo or topical product cannot replicate what a systemic DHT blocker does
This is where a lot of money gets wasted. A significant portion of the hair loss product market is built on ingredients that sound convincing — saw palmetto extract, biotin, caffeine, ketoconazole — some of which have mild or theoretical supporting mechanisms, none of which have the clinical evidence base that finasteride and minoxidil do. The fundamental problem with most topical DHT “blockers” is penetration. Getting an active ingredient through the scalp’s outer barrier in a concentration sufficient to meaningfully inhibit DHT at the follicle level is a different pharmacological challenge from what a shampoo, conditioner, or scalp serum is designed to achieve. The mechanism makes sense in theory. Whether it translates to meaningful results in practice is a very different question.
The hair loss treatment market is large enough, and the emotional vulnerability around hair loss real enough, that scepticism about unproven products is warranted. If a product’s evidence for efficacy comes primarily from brand-funded materials or before-and-after photographs, that’s not the same as clinical trial data. You deserve to know the difference before you spend money on it.
The window of intervention — why acting earlier produces better outcomes
Returning to the plant pot: once a follicle has fully miniaturised — when the pot has effectively reduced to nothing — neither finasteride nor minoxidil is likely to revive it. Finasteride can preserve what you still have. Minoxidil can stimulate follicles that are still weakly active. But neither works well on scar tissue where a follicle used to be.
This is why the window of intervention matters. A follicle producing thin, fine, short hairs is still alive. That’s the moment where treatment is most likely to produce meaningful results. Waiting until the scalp looks visibly bare in affected areas means waiting until many of those follicles have already passed the point of viable intervention. Earlier is not just better in this context. It is functionally different.
What the evidence actually supports
Evidence grade for established treatments
Finasteride and minoxidil are the two interventions with the strongest independent clinical evidence for male pattern hair loss. Their mechanisms are well-understood, their efficacy has been tested in randomised controlled trials, and both are approved by major regulatory bodies including the US FDA. They are not equivalent in what they do or who they’re appropriate for — finasteride in particular carries potential side effects that require a proper clinical consultation, not a self-guided purchase. But in terms of the question “does the evidence support this approach,” the answer for these two is yes, with nuance about individual suitability.
Everything else in the market sits on a spectrum from “plausible but under-researched” to “almost certainly capitalising on hope rather than science.” Low-level laser therapy sits somewhere in the middle — there’s emerging evidence, but study quality and consistency are not yet at the level of the established pharmaceutical interventions. Nutritional supplementation may address a deficiency-driven component of hair loss, but it won’t address DHT-mediated miniaturisation. Pattern recognition is improving — standardised clinical staging of hair loss patterns is becoming more rigorous — but classification is a tool for treatment planning, not a treatment itself.
What to be sceptical about in the broader hair loss product market
The core question to ask about any hair loss product is simple: what mechanism does this target, and what independent evidence exists that it actually does that at the concentration and delivery format in this product? Most products cannot answer both halves of that question satisfactorily. That doesn’t mean every non-pharmaceutical product is useless — a good scalp environment, reduced inflammation, and adequate nutrition all matter for hair health. But they are supporting conditions, not solutions to DHT-mediated follicle miniaturisation. If a product is positioned as an alternative to finasteride or minoxidil without peer-reviewed evidence to support that claim, that positioning is worth questioning.
One thing to do this week based on where you are right now
This week, look at where your hairline or crown is thinning and ask yourself one question: is the hair gone, or is it finer and shorter than it used to be? If the follicle is still producing something — even a weak, thin strand — it is still viable and potentially treatable. If you can see miniaturised hairs rather than completely bare scalp, that is the window where intervention is most likely to be effective. Use that observation to decide whether a conversation with a dermatologist about DHT-blocking treatment is worth having now, rather than in another two years.
If you’d like to explore professional hair loss assessment or treatment options in Singapore, Glamingo lists verified clinics and trichology services where you can get a proper scalp evaluation rather than guessing from a mirror. Find a hair loss specialist near you →
Leave a Reply